Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Apr 10, 2016; 7(2): 160-173
Published online Apr 10, 2016. doi: 10.5306/wjco.v7.i2.160
Published online Apr 10, 2016. doi: 10.5306/wjco.v7.i2.160
Estrogen receptor alpha gene amplification in breast cancer: 25 years of debate
Frederik Holst, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Boston, MA 02215, United States
Frederik Holst, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway
Author contributions: Holst F wrote this review.
Conflict-of-interest statement: Holst F has royalty interest associated with intellectual property of ZytoVision GmbH concerning patent US8101352B2 “Detection of ESR1 Amplification in Breast Cancer” and according EU patent application in the European Union.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Frederik Holst, PhD, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, 450 Brookline Avenue, Boston, MA 02215, United States. frederik.holst@uib.no
Telephone: +1-617-6324515
Received: July 2, 2015
Peer-review started: July 7, 2015
First decision: September 18, 2015
Revised: January 5, 2016
Accepted: February 14, 2016
Article in press: February 16, 2016
Published online: April 10, 2016
Peer-review started: July 7, 2015
First decision: September 18, 2015
Revised: January 5, 2016
Accepted: February 14, 2016
Article in press: February 16, 2016
Published online: April 10, 2016
Core Tip
Core tip: The estrogen receptor alpha gene gene (ESR1) is one of the most important genes in breast cancer, but the prevalence of ESR1 amplification is matter of ongoing debate. A number of studies suggest that technical issues and lack of standards contribute to the discrepant findings. Future studies should focus on the potential clinical relevance of this phenomenon.